KALY - Kali-Extracts Cannabis Biopharma Asset Could Be Undervalued In Light Of GW Pharma $3.5 Billion Market Cap
November 14 2019 - 10:47AM
InvestorsHub NewsWire
KALY – Kali-Extracts Cannabis
Biopharma Asset Could Be Undervalued In Light Of GW Pharma $3.5
Billion Market Cap
Dallas, TX --
November 14, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc.
(Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today highlighted GW Pharmaceuticals $3.5
Billion market capitalization. GW Pharma’s cannabis
biopharmaceutical technology is featured today in a ZACHS Investment Research article. KALY has a
U.S. Patented Cannabis Extraction Process and is developing
treatments for various medical conditions (see below).
Doctors working with KALY on the treatment developments have
compared KALY’s technology to GW Pharma’s and indicated the KALY
solutions could be superior to GW Pharma’s. KALY has recently
announced receiving inquiries into the acquisition of the company’s
cannabis biopharmaceutical technology valuing the technology at $50
million. KALY management is entertaining the inquiries but
indicates that the $50 million valuation is too
low.
KALY’s cannabis
biopharmaceutical technology intellectual property portfolio
contains a deep pipeline of cannabinoid product candidates
including four distinct compounds listed
here:
Chronic Obstructive Pulmonary
Disease (COPD) - The
market for COPD treatment is anticipated to reach $14 billion by
2025;
Type 2
Diabetes - The market for
Type 2 Diabetes is expected to be a $64 billion market by
2026;
Cancer Pain
Management - The overall
pain management treatment market is anticipated to reach $83
billion by 2024, and
Epilepsy
- The market for epilepsy treatment is
anticipated to reach $9 billion by 2022.
In conjunction with the research already conducted
and the next phase of research now moving forward, KALY recently
filed for a new patent application specifically on its formulation
for symptoms associated with COPD and other similar respiratory
conditions. KALY also filed for a trademark
on the name RespRx as the brand name for its CBD
formulation to treat the symptoms associated with COPD and other
similar respiratory conditions. The market
for COPD treatment is anticipated to reach $14 billion by
2025.
In addition to KALY’s ongoing efforts to develop
prescription therapies, KALY has initiated a program to certify its
proprietary CBD extracts derived from KALY’s U.S. Patented
Extraction Process as an Over-The-Counter (OTC) drug under the
requirements prescribed by the U.S. Food and Drug
Administration.
To stay abreast
of the latest developments and learn more about the company visit
https://www.kali-extracts.com/.
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and as such, may involve risks and uncertainties.
These forward looking statements relate to, amongst other things,
current expectation of the business environment in which the
company operates, potential future performance, projections of
future performance and the perceived opportunities in the market.
The company's actual performance, results and achievements may
differ materially from the expressed or implied in such
forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024